IMPAKT 2017: Sponsor & Exhibitor Profiles
F. Hoffmann-La Roche Ltd.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic testing which help support physicians with their complex treatment decisions.
The Agendia Breast Cancer Test Suite includes MammaPrint®, the 70-gene breast cancer recurrence assay and was the first FDA-cleared and only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data and BluePrint®, the 80-gene molecular subtyping assay that identifies Luminal-type, Basal-type and HER2-type breast cancer molecular subtypes.
Together, these tests help physicians reliably improve patient outcomes by making better informed breast cancer treatment decisions. With more definitive answers, and by uncovering more clinically actionable biology, Agendia enables cost effective care with proven outcomes.
Display No. A1
ecancer is a not for profit, independent organisation with over 10 years' experience in providing freely accessible content to the global oncology community.
We have always done things differently to traditional publishers because we believe that only when the financial barriers to accessing research and education are removed, will we take radical steps towards defeating cancer.
To do this we have built a huge online knowledge bank which is freely accessible to all: ecancer.org. We feature videos, e-learning modules and news items, as well as an open access research journal, ecancermedicalscience. We also run events all over the world.
Display No. A5
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.
Display No. B1
The company’s purpose is to empower women with a reliable solution that seamlessly fits into their busy lifestyle. It puts into their hands an innovative m-health solution for in-home breast examination dedicated to all women worldwide regardless of age and breast tissue type. The BRASTER system consists of a high-tech consumer device, user-friendly mobile application, artificial intelligence algorithms detecting breast cancer in an early stage and a telemedical centre with high class medical experts that provide full support to users. BRASTER’s method is user-friendly, safe, non-invasive, painless, radiation-free and comfortable. Many years of clinical trials confirm the high efficacy and usability of the device in the screening of breast cancer.
Display No. A4
Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions. Celgene employs more than 7,000 employees worldwide.